Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors

by Naing, Aung, Fu, Siqing, Zinner, Ralph G., Wheler, Jennifer J., Hong, David S., Arakawa, Kazuhito, Falchook, Gerald S., Kurzrock, Razelle
Published 2013

Evaluation of aerosol IL-2 in sarcoma patients with lung metastases for future combination therapy with infused natural killer cells

by Naing, Aung, Anderson, Pete, Guma, Sergei, Chien, Hsuan-Chu, McQuinn, Lacey MM, Hein, Joshua P, Zinner, Ralph G, Kleinerman, Eugenie S, Gordon, Nancy
Published 2013

Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus

by Liu, Xiaochun, Kambrick, Susan, Fu, Siqing, Naing, Aung, Subbiah, Vivek, Blumenschein, George R., Glisson, Bonnie S., Kies, Merrill S., Tsimberidou, Apostolia M., Wheler, Jennifer J., Zinner, Ralph G., Hong, David S., Kurzrock, Razelle, Piha-Paul, Sarina A.
Published 2016

MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors

by Tang, Chad, Fontes Jardim, Denis L., Falchook, Gerald S., Hess, Kenneth, Fu, Siqing, Wheler, Jennifer J., Zinner, Ralph G., Naing, Aung, Tsimberidou, Apostolia M., De Melo Galgiato, Debora, Westin, Shannon N., Meric-Bernstam, Funda, Kurzrock, Razelle, Hong, David S.
Published 2013

A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701)

by Bepler, Gerold, Zinner, Ralph G, Moon, James, Calhoun, Royce, Kernstine, Kemp, Williams, Charles C, Mack, Philip C, Oliveira, Vasco, Zheng, Zhong, Stella, Philip J, Redman, Mary W, Gandara, David R
Published 2014

Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies

by Janku, Filip, Angenendt, Philipp, Tsimberidou, Apostolia M., Fu, Siqing, Naing, Aung, Falchook, Gerald S., Hong, David S., Holley, Veronica R., Cabrilo, Goran, Wheler, Jennifer J., Piha-Paul, Sarina A., Zinner, Ralph G., Bedikian, Agop Y., Overman, Michael J., Kee, Bryan K., Kim, Kevin B., Kopetz, E. Scott, Luthra, Rajyalakshmi, Diehl, Frank, Meric-Bernstam, Funda, Kurzrock, Razelle
Published 2015

Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies

by Janku, Filip, Angenendt, Philipp, Tsimberidou, Apostolia M., Fu, Siqing, Naing, Aung, Falchook, Gerald S., Hong, David S., Holley, Veronica R., Cabrilo, Goran, Wheler, Jennifer J., Piha-Paul, Sarina A., Zinner, Ralph G., Bedikian, Agop Y., Overman, Michael J., Kee, Bryan K., Kim, Kevin B., Kopetz, E. Scott, Luthra, Rajyalakshmi, Diehl, Frank, Meric-Bernstam, Funda, Kurzrock, Razelle
Published 2015

PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed...

by Zinner, Ralph G., Obasaju, Coleman K., Spigel, David R., Weaver, Robert W., Beck, J. Thaddeus, Waterhouse, David M., Modiano, Manuel R., Hrinczenko, Borys, Nikolinakos, Petros G., Liu, Jingyi, Koustenis, Andrew G., Winfree, Katherine B., Melemed, Symantha A., Guba, Susan C., Ortuzar, Waldo I., Desaiah, Durisala, Treat, Joseph A., Govindan, Ramaswamy, Ross, Helen J.
Published 2015

BRAF mutation testing with a rapid, fully integrated molecular diagnostics system

by Janku, Filip, Claes, Bart, Huang, Helen J., Falchook, Gerald S., Devogelaere, Benoit, Kockx, Mark, Bempt, Isabelle Vanden, Reijans, Martin, Naing, Aung, Fu, Siqing, Piha-Paul, Sarina A., Hong, David S., Holley, Veronica R., Tsimberidou, Apostolia M., Stepanek, Vanda M., Patel, Sapna P., Kopetz, E. Scott, Subbiah, Vivek, Wheler, Jennifer J., Zinner, Ralph G., Karp, Daniel D., Luthra, Rajyalakshmi, Roy-Chowdhuri, Sinchita, Sablon, Erwin, Meric-Bernstam, Funda, Maertens, Geert, Kurzrock, Razelle
Published 2015